24 September 2014
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Exercise of Options
Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces it has made an application to the London Stock Exchange for 188,500 ordinary shares of 0.1p each to be admitted to trading on AIM. Dealing is expected to commence in these shares on 30 September 2014. The ordinary shares have been allotted pursuant to the exercise of options and will rank pari passu in all respects with the existing ordinary share capital of the Company. The total number of shares in issue (inclusive of the above issue) is 410,055,331 Ordinary shares of 0.1p each.
For further information
|
Allergy Therapeutics |
+44 (0) 1903 845 820 |
|
Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director |
|
|
Peel Hunt LLP |
+44 (0) 20 7418 8900 |
|
James Steel Clare Terlouw |
|
|
FTI Consulting |
+44 (0) 20 3727 1000 |
|
Simon Conway Victoria Foster Mitchell |
Notes to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the current financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.
This information is provided by RNS